Botulism is a rare illness caused by a toxin that attack a body’s nerves. Botulism toxin is made by Clostridium botulinum and sometimes Clostridium butyricum and Clostridium baratii bacteria. The symptoms of botulism usually start with weakness of the muscles that control the eyes, face, mouth, and throat. This weakness can further spread to the neck, arms, torso, and legs. Botulism can also weaken the muscles involved in breathing, which can lead to difficulty breathing and can be fatal. The bacteria that make botulinum toxin are found naturally in many places, but it is rare for them to make people sick. It has been observed that more than 90% of the patients with botulism have 3-5 of the following signs or symptoms, nausea, vomiting, dysphagia, diplopia, dilated/fixed pupils, extremely dry mouth unrelieved by drinking fluids.
Some of the drug candidates in the botulism pipeline include, but are not limited to, Botulinum toxin A topical, Botulinum toxin A and Botulinum toxin intravesicular. Some of the companies having drugs in the botulism pipeline includes CytoDel LLC, Hawaii Biotech Inc, Microbiotix Inc. and XOMA Corp.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.